Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Neonatal abstinence and maternal-medicine exposure

Paediatrics and child health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Respiratory depression, seizure or severe feeding failure

Apnoea, cyanosis, reduced consciousness, seizures, profound hypotonia, dehydration or uncontrolled vomiting requires emergency stabilisation and cannot be assumed to be uncomplicated withdrawal.

Action: Stabilise airway, breathing, circulation, temperature and glucose; call neonatal help and assess sepsis, HIE, metabolic disease and intracranial pathology. Obtain an exact maternal medicine and substance timeline, including prescribed opioids, benzodiazepines, antidepressants and medicines given during labour. Provide respiratory support as required. Avoid routine naloxone in an opioid-exposed newborn because it can precipitate abrupt withdrawal; seek toxicology and neonatal pharmacy advice.

Synopsis

Assess newborn effects of prescribed medicines and substance exposure without stigma, distinguish toxicity from withdrawal and other illness, prioritise parent-infant supportive care, and use local neonatal pharmacotherapy safely when functional impairment persists.

  • Use neonatal opioid withdrawal syndrome for opioid-specific withdrawal and neonatal abstinence syndrome when multiple drug classes may contribute; signs are clinical and nonspecific.
  • Obtain a non-judgemental history of prescriptions, over-the-counter products, substitution therapy, alcohol, nicotine, recreational substances, timing, dose, route and last exposure.
  • Opioid withdrawal commonly causes high-pitched cry, tremor, irritability, increased tone, poor sleep, yawning, sneezing, sweating, loose stool, vomiting and disorganised feeding.
  • Late-pregnancy SSRIs can cause transient central, motor, respiratory and gastrointestinal adaptation symptoms; benzodiazepines may cause respiratory depression, floppy infant syndrome or withdrawal.
  • Do not discontinue an essential maternal medicine abruptly during pregnancy or breastfeeding without specialist advice; maternal relapse and withdrawal can harm both parent and baby.
  • First-line care is a quiet low-stimulation environment, skin-to-skin contact, swaddling, cue-based frequent feeds, rooming-in and consistent parental involvement.
  • A function-based assessment asks whether the baby can eat effectively, sleep adequately and be consoled; units may use a validated score but treatment must address function and trend.
  • Support breastfeeding when maternal treatment is stable and no substance-specific contraindication applies; assess illicit use, HIV status, sedation, co-medication and safeguarding individually.
  • Use oral morphine only when opioid withdrawal impairs feeding, sleep or consolability despite optimised non-pharmacological care, following one explicit local neonatal protocol.
  • Phenobarbital may be added by specialists for refractory symptoms or significant non-opioid/polysubstance withdrawal; it does not treat opioid gastrointestinal symptoms as directly.
  • Toxicology testing supports but does not replace history and examination. Obtain consent, know the detection window and avoid punitive interpretation of a single test.
  • Discharge requires stable feeding, growth, sleep and cardiorespiratory state, completion of medicine observation after weaning, safe-care planning and coordinated midwifery, primary-care and social follow-up.

Key red flags

Apnoea, bradycardia, cyanosis or marked sedation soon after birth suggests drug effect, respiratory disease, infection or HIE rather than withdrawal alone.

Seizures, focal neurological signs, bulging fontanelle, persistent abnormal tone or hypoglycaemia requires a full neurological and metabolic assessment.

Fever, poor perfusion, respiratory distress or rising inflammatory concern raises sepsis; irritability and temperature instability are not specific to withdrawal.

Bilious vomiting, abdominal distension, blood in stool, weight loss or dehydration requires urgent gastrointestinal and feeding assessment.

Unexplained bruising, inconsistent exposure history, unsafe caregiving, domestic abuse or parental intoxication prompts proportionate safeguarding assessment while maintaining compassionate care.

Polysubstance exposure, long-acting opioids, benzodiazepines or SSRI exposure may delay or prolong symptoms and require an observation plan tailored to pharmacology.

Investigation priorities

01
First-line: clinical and functional assessmentFirst stepFirst line

Establish whether the baby can feed, sleep, be consoled and maintain physiological stability.

Management branches

Before birthPlan exposure-aware care

A medicine or substance with possible newborn effects is identified antenatally.

  1. Obtain specialist risk assessment without abrupt maternal cessation.
  2. Agree birth-site, observation, feeding, breastfeeding, maternal analgesia and safeguarding plans.
  3. Communicate exact exposures confidentially to the neonatal and postnatal teams.
After birthSupport regulation

The baby is stable but at risk of adaptation or withdrawal.

  1. Keep parent and baby together where safe, reduce noise and light and use skin-to-skin and swaddling.
  2. Support frequent cue-based feeds and monitor functional eating, sleeping, consolability, weight and cardiorespiratory state.
  3. Use the unit assessment tool at specified intervals and treat alternative illness promptly.

Key medicines

Morphine sulfate oral solutionOne current NHS Greater Glasgow and Clyde neonatal protocol starts 60 micrograms/kg orally every 4 hours for significant opioid withdrawal, increasing by 10 micrograms/kg per dose daily to a maximum 80 micrograms/kg every 4 hours before specialist review and later gradual weaning. Other UK units use different schedules.This is an explicitly labelled regional example, not a national universal dose. Verify concentration, current weight and local guideline; use independent checks. Monitor sedation, apnoea, oxygenation, feeding and constipation and avoid rapid weaning.
Phenobarbital oral or intravenousUse only the exact neonatal loading, maintenance and level-monitoring regimen in the treating unit's formulary when specialist review identifies refractory symptoms or important non-opioid or polysubstance withdrawal.Sedation may worsen feeding and obscure neurological illness; respiratory depression and accumulation occur, especially with hepatic dysfunction or concomitant morphine. It does not address all opioid gastrointestinal signs and requires planned weaning.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • UKTIS selective serotonin reuptake inhibitors in pregnancyCurrent UK risk framing, neonatal adaptation and monitoring advice.
  • UKTIS diazepam in pregnancyNeonatal respiratory depression, floppy infant syndrome and withdrawal after late or prolonged exposure.
  • UKTIS pain management in pregnancyOpioid neonatal respiratory depression and withdrawal risk in maternal analgesia.
  • NHS GGC neonatal abstinence syndrome guidelineExplicitly regional clinical assessment, supportive-care and morphine example; local protocols vary.
  • NICE NG194 postnatal care recommendationsNewborn feeding, safe care and postnatal assessment framework.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting review
JurisdictionUnited Kingdom